AHA: AMG145 Lowers LDL Levels in Statin-Intolerant

Subcutaneously administered monoclonal antibody to PCSK9 efficacious and tolerable

WEDNESDAY, Nov. 7 (HealthDay News) -- Subcutaneously administered AMG145, a monoclonal antibody to plasma proprotein convertase subtilisin/kexin type 9 (PCSK9), correlates with significant reductions in low-density lipoprotein cholesterol (LDL-C) levels in patients who are intolerant to statins due to muscle-related side effects, according to research published online Nov. 5 in the Journal of the American Medical Association to coincide with presentation at the American Heart Association's Scientific Sessions 2012, held from Nov. 3 to 7 in Los Angeles.

David Sullivan, M.D., of the Royal Prince Alfred Hospital in Camperdown, Australia, and colleagues assessed the efficacy and tolerability of AMG145 in patients with statin intolerance in a 12-week randomized, double-blind, placebo- and ezetimibe-controlled, dose-ranging study. Participants included 160 adults who were randomized equally to one of five groups: AMG145 at doses of 280, 350, or 420 mg; AMG145 420 mg plus 10 mg ezetimibe; or placebo plus 10 mg ezetimibe. Placebo and AMG145 were administered subcutaneously every four weeks.

The researchers found that, at week 12, the mean changes in LDL-C were −41, −43, and −51 percent for the AMG145 280 mg, 350 mg, and 420 mg groups, respectively, and −63 percent for the 420 mg AMG145 plus ezetimibe group, all of which were significantly different from the −15 percent for placebo/ezetimibe. AMG145 was associated with reports of four serious adverse events and the most common treatment-emergent adverse event was myalgia.

"In this phase 2 study of patients selected on the basis of prior statin intolerance, treatment with subcutaneous administration of a monoclonal antibody to PCSK9, AMG145, achieved significant reductions in LDL-C and was associated with short-term tolerability," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Amgen, which funded the study and manufactures the study drug.

Full Text
More Information

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events